Analysts on Wall Street project that Health Catalyst (HCAT) will announce quarterly earnings of $0.01 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $69.34 million, declining 12.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Health Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Professional services' should arrive at $19.93 million. The estimate suggests a change of -28.7% year over year.
The consensus among analysts is that 'Revenue- Technology' will reach $49.51 million. The estimate suggests a change of -3.8% year over year.
Analysts forecast 'Adjusted Gross Profit- Professional Services' to reach $3.34 million. The estimate is in contrast to the year-ago figure of $4.44 million.
Analysts expect 'Adjusted Gross Profit- Technology' to come in at $32.74 million. The estimate compares to the year-ago value of $34.61 million.
View all Key Company Metrics for Health Catalyst here>>>Over the past month, Health Catalyst shares have recorded returns of +52.4% versus the Zacks S&P 500 composite's +11.4% change. Based on its Zacks Rank #4 (Sell), HCAT will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Health Catalyst, Inc. (HCAT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).